Compare Abeona Therapeutics Inc (ABEO) vs Anheuser-Busch Inbev SA (BUD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Anheuser-Busch Inbev SA — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Anheuser-Busch Inbev SA trades at $79.5 (market cap $155.34B). The key difference: Anheuser-Busch Inbev SA is far larger — about 416.1× Abeona Therapeutics Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.69% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BUD | |
|---|---|---|
Market Cap | $373.32M | $155.34B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $85.09 |
52-Week Low | $4.17 | $57.10 |
Enterprise Value | $228.22M | $216.53B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BUD trades at $79.74, down 1.95% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, maintains healthy profit margins (net income margin 11.9%), and shows improving cash flow trends. Recent news highlights premiumization strategies and digital expansion efforts to drive growth amid changing consumer preferences in the beverage-alcohol industry.
The outlook remains positive with analyst consensus pointing to 13% upside to the $90.08 price target. Key opportunities include continued earnings momentum and dividend yield support, while risks involve alcohol consumption trends and competitive pressures. The stock presents a compelling value proposition for investors seeking stable returns with moderate growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →
